An investigation of efficacy, safety, and prognostic factors of drug‐eluting beads‐transarterial chemoembolization operation with CalliSpheres^® Microspheres in treating Chinese hepatocellular carcinoma patients

Abstract

BackgroundWe aimed to investigate treatment response, survival profiles, safety profiles, and predictive factors of drug‐eluting beads‐transarterial chemoembolization (DEB‐TACE) with CalliSpheres® Microspheres (CSM) in treating Chinese hepatocellular carcinoma (HCC) patients.MethodsA total of 66 HCC patients about to receive DEB‐TACE with CSM therapy were consecutively enrolled in this prospective cohort study. Treatment response was recorded. Besides, progression‐free survival (PFS) and overall survival (OS) were also recorded. All adverse events including pain, nausea, vomiting, fever, and liver function damage were recorded during hospitalization.Results37.9% of patients achieved complete response (CR) and 81.8% of patients achieved an objective response rate (ORR). For survival, mean PFS and OS were 13.7 (11.7‐15.8) months and 18.8 (95% CI: 16.3‐21.2) months, respectively. Multivariate logistic regression analysis revealed that a number of nodules ≥2 was an independent factor for worse CR; moreover, multivariate Cox's regression analysis disclosed that largest sample size ≥5 cm was an independent factor for shorter PFS, and Child‐Pugh B and BCLC stage B/C were independent predictive factors for unfavorable OS. As to AEs, numbers of patients suffered liver function damage, pain, nausea, vomiting, and fever were 29 (43.9%), 27 (40.9%), 22 (33.3%), 13 (19.7%), and 37 (56.1%), respectively.ConclusionDrug‐eluting beads‐transarterial chemoembolization with CSM is an effective and tolerated treatment for Chinese HCC patients, and number of nodules ≥2, largest nodule size ≥5 cm, Child‐Pugh stage B, and BCLC stage B/C correlates with unfavorable prognosis.

Treatment Response, Survival, and Safety of Transarterial Chemoembolization With CalliSpheres® Microspheres Versus Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma: A Meta-Analysis

“…doxorubicin, pirarubicin, and arsenic trioxide) in a stable fashion by ion-changing in target sites ( 8 – 10 ). Owing to several outstanding features such as satisfactory biocompatibility, adequate physicochemical stability, high drug-loading efficacy and stable releasing profiles (over two weeks), transarterial chemoembolization with CSM (CSM-TACE) is widely applied in treating Chinese HCC patients ( 8 , 11 – 13 ). However, comparisons of efficacy and safety between dTACE and cTACE remains controversial ( 14 – 16 ).…”

Targeting Ca2+ Signaling in the Initiation, Promotion and Progression of Hepatocellular Carcinoma

“…Of particular interest in considering the potential administration of therapeutic agents targeted to Ca 2+ -signaling pathways in HCC is drug-emitting bead transcatheter arterial chemoembolization. This is employed to deliver therapeutic agents to the site of tumors in the treatment of HCC patients with intermediate stage HCC which cannot be treated surgically [ 67 , 68 , 69 ]. Examples of chemotherapeutic agents delivered by drug-emitting bead transcatheter arterial chemoembolization include doxorubicin, cisplatin, oxaliplatin and arsenic trioxide.…”

“…In principle, this involves the intra-arterial injection to the site of a tumor of a viscous emulsion composed of a drug-emitting bead (e.g., CalliSpheres microspheres) mixed with iodized oil to deliver one or more chemotherapeutic agents to the site of the tumor. This is followed by embolization of the blood vessel with gelatine sponge particles which confines the chemotherapeutic agent to the vicinity of the tumor and creates an ischemic environment which assists in killing HCC cells [ 67 , 68 , 69 ].…”

Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma

“…However, the OS of DEB-TACE in patients with large or huge HCC is still not satisfactory, with a median OS of only 13.0–16.0 months. 12 , 13 One reason is that complete embolization of HCC with large tumor burden by one single procedure could cause serious embolization-related adverse events (AEs), such as serious post-embolization syndrome, liver/renal dysfunction, biliary injury, and liver abscess, 14 , 15 so DEB-TACE with multiple procedures is recommended for large or huge HCC. 16 However, the residual arterial supply following each embolization may contribute to the progression of residual tumor.…”